Cidara stock surges as H.C. Wainwright raises price target on trial data

H.C. Wainwright raised its price target on Cidara Therapeutics (CDTX) to $53 from $41, maintaining a Buy rating, following highly positive Phase 2b trial results for its influenza prevention drug, CD388. The NAVIGATE trial met its primary and all secondary efficacy endpoints, demonstrating up to 76% protection against symptomatic influenza over 24 weeks with a single subcutaneous dose, significantly surpassing average vaccine efficacy. The drug was also well-tolerated with no safety signals, indicating a clinically meaningful advancement in influenza prophylaxis and strong potential for the company.

Analysis

H.C. Wainwright has materially increased its price target on Cidara Therapeutics (CDTX) to $53.00 from $41.00, while reaffirming a Buy rating, in direct response to successful Phase 2b trial results for its influenza drug candidate, CD388. The NAVIGATE trial demonstrated that a single dose of CD388 provided significant protection against symptomatic influenza, achieving efficacy rates of 76%, 61%, and 58% at the 450mg, 300mg, and 150mg doses, respectively, over a 24-week period. This performance is notably superior to the approximate 40% efficacy of average seasonal vaccines and surpasses the analyst's success criterion of 50%. The trial met all primary and secondary endpoints, with efficacy maintained through 28 weeks. Crucially, CD388 was reported as well-tolerated with no safety signals, a critical factor that de-risks its clinical profile and supports the analyst's view that the results are both "successful and clinically meaningful."

Key Decisions for Investors

• The highly positive Phase 2b data, showing efficacy up to 76% versus the ~40% for typical vaccines, significantly de-risks CD388 and supports a bullish outlook on Cidara Therapeutics.
• Investors should consider the new $53 price target from H.C. Wainwright as a key valuation data point, reflecting increased confidence in the asset's commercial potential following this clinical milestone.
• While the results are strong, focus should now shift to the company's strategy and timeline for advancing CD388 into pivotal Phase 3 trials and its subsequent engagement with regulatory authorities.